Ex Vivo and In Vivo Assessments of Angiogenesis, Blood Flow and Vasoactive Capability
Cardiovascular disease remains a continuing health threat for much of the world’s population. Basic discoveries utilizing cell based assays provide initial insights into signaling pathways and potential molecular targets for developing novel therapeutics. These targets must be validated in more complex vascular cell systems through in vivo models of vascular responses to assess their potential efficacy and specificity. We have focused on developing several models that recapitulate angiogenic responses, vascular cell activity and in vivo blood flow dynamics to provide such clinically relevant data. Our models have been optimized to be technically straightforward for those not experienced in using composite tissue assays and/or animal work in the hope that these approaches will become more accessible to basic scientists. Our focus on small mammals and in particular mice is based on our belief that studying vascular responses in genetically altered animals where target genes are knocked out, knocked in, or conditionally expressed provides powerful insights into the pathogenesis of vascular disease and therapeutic opportunities. Therapeutic strategies developed in mice must also be validated in higher mammals to estimate their potential for treating human disease.
KeywordsVascular Smooth Muscle Cell Hind Limb Blood Oxygen Level Dependent Angiogenic Response Full Thickness Skin Graft
- 23.Das M, Aronow WS, McClung JA, Belkin RN (2006) Increased prevalence of coronary artery disease, silent myocardial ischemia, complex ventricular arrhythmias, atrial fibrillation, left ventricular hypertrophy, mitral annular calcium, and aortic valve calcium in patients with chronic renal insufficiency. Cardiol Rev 14:14–17PubMedCrossRefGoogle Scholar
- 27.Isenberg JS, Hyodo F, Pappan LK, Abu-Asab M, Tsokos M, Krishna MC, Frazier WA, Roberts DD (2007) Blocking thrombospondin-1/CD47 signaling alGoogle Scholar
- 31.Schneeberger H, Aydemir S, Illner WD, Land W (1997) Nonspecific primary ischemia/reperfusion injury in combination with secondary specific acute rejection-mediated injury of human kidney allografts contributes mainly to development of chronic transplant failure. Transplant Proc 29:948–949PubMedCrossRefGoogle Scholar